A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
← catalyst calendarNCT05060016 · readout in 497 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
222actual
Sites
80
Countries
Austria, Belgium, Denmark +15
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-01 | actual | When the study began enrolling |
| Primary completion | 2027-12-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-30 | estimated | The whole study's end, after follow-up |
| First posted | 2021-09-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Small Cell Lung Cancer
Intervention
- Drug: Tarlatamab
Primary outcomes
what the primary-completion date above is the date OFPart 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator
measured Up to a maximum of 61 months
Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events
measured Up to a maximum of 61 months
Part 1 Only: Serum Concentrations of Tarlatamab
measured Up to a maximum of 24 months
Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR)
measured Up to a maximum of 61 months
Publications
- PMID 37861218 — cited as background
- PMID 39530627 — cited as background
- PMID 40025391 — cited as background
- PMID 40261494 — cited as background
- PMID 40908346 — cited as background
- PMID 40928991 — cited as background
- PMID 41015335 — cited as background
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed